Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was also under development for the treatment of idiopathic/primary membranous nephropathy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Drugs Clinical Trials 100

BioTech 365

AUGUST 4, 2021

the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → Chino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.

Manufacturing 40

Manufacturing Generic Pharmaceutical Production Development 40

Pharmaceutical Technology

DECEMBER 22, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Insulin 130

Insulin Production Development Genetics 130

Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was under development for renal cell carcinoma as first line therapy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

XTalks

DECEMBER 14, 2020

AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. According to AvKARE, the error occurred at a third-party bottle filling facility.

Packaging 52

Packaging Packaging Drugs Generic Pharmaceutical 52

XTalks

JUNE 8, 2022

Biosimilars are generic versions of biologics medicines that already have regulatory approval (called the reference product) and have expired patents leading to a loss of exclusivity rights. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.

Generic Pharmaceutical 69

Generic Pharmaceutical Production Medicine Branding 69

The Pharma Data

NOVEMBER 5, 2020

and Aavis Pharmaceuticals Inc. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. YARDLEY, Pa.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

The Pharma Data

MARCH 15, 2022

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks. Today, the U.S.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

The Pharma Data

JANUARY 4, 2021

Meiji Seika Pharma, since it launched penicillin in Japan in 1946, has been providing high-quality pharmaceutical products such as antibiotics, antidepressants and antipsychotics in Japan and overseas. Integrated Reports: [link].

Generic Pharmaceutical 40

Generic Pharmaceutical Generic Drugs Clinical Development Clinical Research 40

The Pharma Data

OCTOBER 27, 2020

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. A playback of the call will be archived and accessible on the same website for at least three months. About Lannett Company, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical Packaging Packaging Manufacturing 40

The Pharma Data

MAY 8, 2021

There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

DECEMBER 23, 2020

COVAXX will supply the bulk product and Aurobindo will manufacture the finished doses at its facilities in Hyderabad, India. Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

The Pharma Data

DECEMBER 23, 2020

. Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN), headquartered at Hyderabad, India , manufactures generic pharmaceuticals and active pharmaceutical ingredients. The Company is marketing these products globally, in over 150 countries.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

MAY 18, 2021

Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients. As part of this network modernization plan, Sandoz will phase out the current production of oral APIs at the Les Franqueses site in Spain, which it plans to close in 2024.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

Pharma in Brief

SEPTEMBER 19, 2023

The Plaintiffs (Boehringer companies) allege that the Defendants (generic pharmaceutical companies) would infringe six Canadian patents if allowed to market generic empagliflozin products. In defence, the Defendants allege that the patents are invalid.

Regulation 52

Regulation Generic Pharmaceutical Compliance Medicine 52

The Pharma Data

MAY 2, 2021

There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

OCTOBER 26, 2021

Q3 core¹ operating income grew +9% (cc, +10% USD) Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Sandoz declined -15% (cc, -13% USD), impacted by gross margin Q3 operating income grew +32% (cc, +34% USD) Q3 net income increased +41% (cc, +43% USD) Q3 free cash flow 1 of USD 4.4

Medicine 52

Medicine Sales Marketing Clinical Trials 52

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 15, 2023

Yannis Skoufalos , former Global Product Supply Officer at Procter & Gamble between 2011 and 2019, a US-headquartered consumer goods company with approximately USD 81 billion in sales for the year ending in March 2023. Nor can there be any guarantee that such products will be commercially successful in the future.

Sales 40

Sales Production Doctor Doctors 40

Pharma in Brief

DECEMBER 3, 2023

The Regulations became a moving target for the innovative and generic pharmaceutical industries, being amended seven times between 1998 and 2016. These provisions were further amended in 2015 to clarify the level of product specificity required for combination drugs and formulations. Frequent amendments (1998–2016).

Regulation 52

Regulation Compliance Medicine Manufacturing 52

FDA Law Blog

OCTOBER 29, 2023

This guidance was based on stakeholder feedback that the current FDA Birth Control Guide may not identify all and/or newer contraceptive products approved, cleared, or granted by FDA.

FDA Approval 45

FDA Approval Production Generic Pharmaceutical Pharmacy 45

FDA Law Blog

JANUARY 24, 2024

If this vision is achieved, the United States can bring innovative biotechnologies and products to markets faster while building a more robust supply chain ecosystem. capacity and technologies to support small molecule API production, including the impact of key starting material availability on U.S.

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69